Page 7 - 2018_11-Haematologica-web

Table of Contents
Volume 103, Issue 11: November 2018
Cover Figure
haematologica Journal of the European Hematology Association
Published by the Ferrata Storti Foundation
Bone marrow smear from a patient with myelodysplastic syndrome showing a group of micromegakaryocytes. Courtesy of Prof. Rosangela Invernizzi.
Editorials
1753 Loss-of-function ferroportin disease: novel mechanistic insights and unanswered questions L. Tom Vlasveld and Dorine W. Swinkels
1756 To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia
Joshua T. Schiffer and Charles A. Schiffer
1758 Older adults with acute myeloid leukemia treated with intensive chemotherapy: “old” prognostic algorithms may not apply Richard M. Stone and Coleman Lindsley
Review Article
1760 Preclinical human models and emerging therapeutics for advanced systemic mastocytosis Michel Arock et al.
Guideline Article
1772 European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when Jo Caers et al.
Articles
Hematopoiesis
1785 Alas1 is essential for neutrophil maturation in zebrafish Junwei Lian et al.
Iron Metabolism & its Disorders
1796 The SLC40A1 R178Q mutation is a recurrent cause of hemochromatosis and is associated with a novel pathogenic mechanism Chandran Ka et al.
Bone Marrow Failure
1806 Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A Jennifer E. Adair et al.
Phagocyte Biology & its Disorders
1815 Prognostic factors of Erdheim–Chester disease: a nationwide survey in Japan Takashi Toya et al.
Chronic Myeloid Leukemia
1825 Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data
Artur C. Fassoni et al.
1835 Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan
Naoto Takahashi et al.
Acute Myeloid Leukemia
1843 Inhibition of protein disulfide isomerase induces differentiation of acute myeloid leukemia cells Justyna Chlebowska-Tuz et al.
Haematologica 2018; vol. 103 no. 11 - November 2018 http://www.haematologica.org/